Staphylococcus aureus News and Research

RSS

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.

Prisoners need education on the appropriate use of topical antibiotic products

Prisoners need education on the appropriate use of topical antibiotic products, according to a study released today at the 39th Annual Educational Conference and International Meeting of the Association for Professionals in Infection Control and Epidemiology.

4 Jun 2012

USPTO issues patent to MicuRx’s MRX-I antibacterial agent

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that the U.S. Patent and Trademark Office (USPTO) issued a composition of matter patent covering its clinical candidate, MRX-I. MRX-I is a novel antibacterial oxazolidinone that targets infections due to multi-drug resistant Gram-positive pathogens.

23 May 2012

Scientists determine genetic sequences of all 12 vancomycin-resistant staph strains

National Institutes of Health-funded scientists have determined the genetic sequences of all 12 available strains of Staphylococcus aureus bacteria resistant to vancomycin-an antibiotic of last resort-and have demonstrated that resistance arose independently in each strain after it acquired a specific bit of genetic material called transposon Tn1546

23 May 2012

Scientists trace origin and development of vancomycin-resistant S. aureus

National Institutes of Health-funded scientists have determined the genome sequences of a dozen strains of Staphylococcus aureus bacteria known to be resistant to vancomycin, an antibiotic of last resort. The researchers demonstrated -that resistance arose independently in each strain, and identified shared features among the strains that may have helped them acquire vancomycin resistance and evade human immune defenses.

23 May 2012

MRSA nasal colonization associated with increase in SSI in patients undergoing GI surgery

Methicillin-resistant Staphylococcus (MRSA) nasal colonization is associated with longer hospital stays and an increase in surgical site infections (SSI) in patients undergoing major gastrointestinal surgery, according to a new study from Scott and White Memorial Hospital, Temple, TX.

21 May 2012

Killer coating destroys bacteria and fungi on contact

Better than antibiotics, it is being used in contact lenses to prevent infections and biomedical products are the next stage

11 May 2012

NovaDigm reports positive data from Phase 1 NDV-3 vaccine program

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data for its NDV-3 vaccine program in a second Phase 1 study.

7 May 2012

Strong link between HAIs and patient readmission after initial hospital stay

New research finds a strong link between healthcare-associated infections (HAIs) and patient readmission after an initial hospital stay. The findings, published in the June 2012 issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America (SHEA), suggest that reducing such infections could help reduce readmissions, considered to be a major driver of unnecessary healthcare spending and increased patient morbidity and mortality.

5 May 2012

Bacteria in belly buttons, armpits, and chronic wounds

Minutes after you were born, bacteria moved in. Since then, their populations have exploded, diversified and spread—on your skin and eyes and in your mouth and gut, not to mention other places. These bacterial cells now far outnumber your own cells.

30 Apr 2012

ICDs may increase risk of complications in patients with infective endocarditis

Patients with infective endocarditis involving implanted cardiac devices experience a high rate of complications such as valve infections, heart failure, and persistent bacteremia, and high in-hospital and 1-year mortality rates, particularly if there is valve involvement, according to a study in the April 25 issue of JAMA.

24 Apr 2012

MicuRx completes MRX-I Phase 1 trial on MRSA and VRE infection

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the completion of its Phase 1 clinical trial for MRX-I, its first development-stage antibiotic drug candidate.

23 Apr 2012

Study shows how MRSA epidemics may emerge and spread at molecular level

National Institutes of Health (NIH) scientists and their colleagues in China have described a rapidly emerging Staphylococcus aureus gene, called sasX, which plays a pivotal role in establishing methicillin-resistant S. aureus (MRSA) epidemics in most of Asia.

23 Apr 2012

Babies rarely became ill from MRSA infections: Study

The need to swab the noses of pregnant women and newborns for the presence of MRSA (methicillin-resistant Staphylococcus aureus) may be unfounded, according to a Vanderbilt study now available online and published in the May issue of Pediatrics.

20 Apr 2012

MDI to advance Detect-Ready MRSA Panel with $1.9M Series B recapitalization financing

Molecular Detection Inc., a company developing Detect-Ready® tests designed to increase the speed and accuracy of infectious disease diagnosis, today announced that it has completed a $1.9 million Series B recapitalization financing.

16 Apr 2012

Study shows how biofilms form on implanted devices

Bacteria such as Staphylococcus aureus, the 'superbug' behind MRSA, can be a major problem for patients who have a medical implant, such as a replacement heart valve or pacemaker.

11 Apr 2012

Akorn launches generic Vancocin for treatment of CDAD

Akorn, Inc., a niche specialty pharmaceutical company, today announced that it has launched Vancomycin Hydrochloride USP 125mg and 250mg capsules, the generic version of ViroPharma's Vancocin, which is indicated for the treatment of Clostridium difficile-associated diarrhea.

10 Apr 2012

FDA clears BD MAX assay for detecting GBS DNA in Lim Broth cultures

BD announced today the U.S. Food and Drug Administration clearance of the BD MAX Group B Streptococcus (GBS) Assay and Clinical Laboratory Improvement Amendments (CLIA) moderate complexity test categorization on the second-generation BD MAX System.

From BD (Becton, Dickinson and Company) 29 Mar 2012

ACS symposium focuses on biomimetics

Combining the secrets that enable water striders to walk on water and give wood its lightness and great strength has yielded an amazing new material so buoyant that, in everyday terms, a boat made from 1 pound of the substance could carry five kitchen refrigerators, about 1,000 pounds.

27 Mar 2012

Infection preventionists, healthcare epidemiologists play key roles in promoting antimicrobial stewardship

Infection preventionists and healthcare epidemiologists play key roles in promoting effective antimicrobial stewardship in collaboration with other health professionals, according to a joint position paper published today by the Association for Professionals in Infection Control and Epidemiology (APIC) and the Society for Healthcare Epidemiology of America (SHEA) in their respective peer-review journals, the American Journal of Infection Control and Infection Control and Hospital Epidemiology.

20 Mar 2012

Bend Research announces licensing agreement with Affinium

Bend Research Inc., a leading independent drug-formulation development and manufacturing company, today announced a licensing agreement with Affinium Pharmaceuticals, Ltd.

13 Mar 2012